Header Logo

Connection

Christopher Desmond to Infliximab

Back to Details
This is a "connection" page, showing publications Christopher Desmond has written about Infliximab.
Christopher Desmond
Connection Strength
0,041
Infliximab
  1. Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort. Intern Med J. 2019 06; 49(6):753-760.
    View in: PubMed
    Score: 0,041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.